At least one chemical entity chosen from compounds of Formula 1and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein.Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described.Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.本發明說明至少一種選自式1化合物及其醫藥學上可接受之鹽、溶劑合物、螯合物、非共價複合物、前藥及混合物之化學實體：並說明包含本發明之至少一種化學實體連同至少一種選自載劑、佐劑及賦形劑之醫藥學上可接受之媒劑的醫藥組合物。並說明治療罹患對抑制Btk活性及/或B細胞活性起反應之特定疾病之患者的方法。並說明用於判定樣本中Btk存在之方法。
